Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34499874

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Oct
First author
Pinto C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Nov;18(11):676. doi: 10.1038/s41571-021-00566-1.
    note
    Source null
    related pmid
    34580476
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Dec;22(12):e532. doi: 10.1016/S1470-2045(21)00640-9.
    note
    Source null
    related pmid
    34856142
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Dec;22(12):e533. doi: 10.1016/S1470-2045(21)00666-5.
    note
    Source null
    related pmid
    34856143
    relationship
    Comment in

Authors and identifiers

  1. name
    Pinto C
    type
    Author
  2. name
    Zucali PA
    type
    Author
  3. name
    Pagano M
    type
    Author
  4. name
    Grosso F
    type
    Author
  5. name
    Pasello G
    type
    Author
  6. name
    Garassino MC
    type
    Author
  7. name
    Tiseo M
    type
    Author
  8. name
    Soto Parra H
    type
    Author
  9. name
    Grossi F
    type
    Author
  10. name
    Cappuzzo F
    type
    Author
  11. name
    de Marinis F
    type
    Author
  12. name
    Pedrazzoli P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Pinto C
    type
    Author
  2. name
    Zucali PA
    type
    Author
  3. name
    Pagano M
    type
    Author
  4. name
    Grosso F
    type
    Author
  5. name
    Pasello G
    type
    Author
  6. name
    Garassino MC
    type
    Author
  7. name
    Tiseo M
    type
    Author
  8. name
    Soto Parra H
    type
    Author
  9. name
    Grossi F
    type
    Author
  10. name
    Cappuzzo F
    type
    Author
  11. name
    de Marinis F
    type
    Author
  12. name
    Pedrazzoli P
    type
    Author
bibliography ids
  1. nci-bib-f4396e14e64a86e50c510be6
book metadata
content sha256
71490ac2faaf9bb2a7d5b4ab570a626fcf8ce376e6217bb452400b8ca286e94c
document type
citation
dois
  1. 10.1016/S1470-2045(21)00404-6
electronic publication date
display
2021 Sep 6
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34499874
immutable id
pubmed:34499874@71490ac2faaf9bb2a7d5b4ab570a626fcf8ce376e6217bb452400b8ca286e94c
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1438-1447
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2021 Nov;18(11):676. doi: 10.1038/s41571-021-00566-1.
    note
    Source null
    related pmid
    34580476
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2021 Dec;22(12):e532. doi: 10.1016/S1470-2045(21)00640-9.
    note
    Source null
    related pmid
    34856142
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2021 Dec;22(12):e533. doi: 10.1016/S1470-2045(21)00666-5.
    note
    Source null
    related pmid
    34856143
    relationship
    Comment in
outcomes validated
false
pmid
34499874
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
f725de06d83c0477539e444c7ae05ba528ae254e4f8dbcfdaee20bda41d6ed15
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Oct
precision
month
year
2021
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34499874/
title
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.

Preserved source evidence · Not medical advice